NCT06732492View on ClinicalTrials.gov

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

NK T-Cell LymphomaCART TherapyCD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

Interventions

DRUG

RD13-02 cell infusion

CAR-T cells

Trial Locations (1)

430022

RECRUITING

Union Hospital, Wuhan

All Listed Sponsors

collaborator

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06732492 - RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies | Biotech Hunter | Biotech Hunter